CORE-019: EARLY PHASE CLINICAL RESEARCH SUPPORT (EPCRS) PROJECT SUMMARY / ABSTRACT A major area of institutional support for clinical cancer research is for investigator-initiated trials. The arrival of new investigators into the OSUCCC, the increased attention paid to translational research and changes in the funding landscape of clinical trials requires that there be a mechanism for funding investigator initiated studies of novel agents and/or novel design. The support of innovative Phase I trials and pilot studies was previously supported by the CCSG-mandated Protocol Specific Research Support mechanism. With the recent changes in the CCSG guidelines, the Early Phase Clinical Research Support (EPCRS) mechanism has been employed since late 2013 as a means of stimulating the conduct of early phase, investigator-initiated studies. The EPCRS process is overseen by Dr. William Carson, the Associate Director for Clinical Research (ADCR). Investigators are informed of this OSUCCC support mechanism via official communications from OSUCCC administration and the Disease Specific Research Group (DSRG) leaders. There is a formal application process which is conducted quarterly. Proposals are reviewed by a panel, chaired by the ADCR, Dr. William Carson. Successful applications are selected for CCSG support in the form of research nurse or data management assistance from the CCC supported Clinical Trials Office (CTO). On average 1-3 studies have been approved for support each quarter. In the current funding cycle, a total of 13 studies have been supported by the EPCRS and have accrued a total of 175 patients in the last year. In addition, to EPCRS, the OSUCCC has a formal, peer-reviewed mechanism, called the Intramural Research Program (IRP), to channel developmental funds from Pelotonia, our annual bicycle fundraising event, into bench to beside research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-44
Application #
9843880
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Reeves, Katherine W; Pennell, Michael; Foraker, Randi E et al. (2018) Predictors of vasomotor symptoms among breast cancer survivors. J Cancer Surviv 12:379-387

Showing the most recent 10 out of 2602 publications